Three Motley Fool contributors think they've found unstoppable dividend stocks to buy right now. Here's why they picked ...

Pfizer's forward dividend yield currently stands at 6.86%. This yield is so attractive that I wondered if it's the highest of ...

Pfizer's diversified pipeline and new product launches are driving operational growth. Click here to read more about PFE ...

Pfizer Inc. (NYSE:PFE) discovers, develops, markets, and sells biopharmaceutical products in the U.S. and internationally. It ...

The stock has a high ceiling heading into next year. 10 stocks we like better than Pfizer › It's been a tough stretch for pharmaceutical giant Pfizer (NYSE: PFE). The company enjoyed a vaccine ...

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate PFE stock a Sell.

A Fallen Giant Pfizer (NYSE:PFE) has been a bitter pill for investors to swallow. Down 19% from its 52-week high of $30.43 per share, PFE stock has plummeted over 50% in the past three years, a stark ...

Realty Income is a real estate investment trust that has raised its dividend payout 131 times since 1994. Verizon's a ...

Looking ahead, Pfizer Inc. (NYSE:PFE) plans to achieve $7.2 billion in cost savings by 2027, which should improve cash flow and provide more flexibility for sustaining its dividend.

These three dividend stocks are trading on the cheap given their true valuations. They should be on income investors' radars.

Enanta Pharmaceuticals has initiated legal action against Pfizer (PFE) over a patent infringement related to Paxlovid, ...